Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1405&sort=-funder_divisions
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=-funder_divisions", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1405&sort=-funder_divisions", "next": null, "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1404&sort=-funder_divisions" }, "data": [ { "type": "Grant", "id": "12399", "attributes": { "award_id": "1U01GH002402-01", "title": "Integrated Public Health and Academic Collaboration for Infectious Diseases Control (iPHAC-IDC): Implementation of One Health approaches to pandemic preparedness and adolescent HIV prevention", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2023-09-30", "end_date": "2028-09-29", "award_amount": 400000, "principal_investigator": { "id": 28341, "first_name": "Supaporn", "last_name": "Wacharapluesadee", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2095, "ror": "https://ror.org/028wp3y58", "name": "Chulalongkorn University", "address": "", "city": "", "state": "", "zip": "", "country": "THAILAND", "approved": true }, "abstract": "Public health threats including emerging infectious diseases (EIDs) have highlighted the need for strengthening surveillance and laboratory systems for faster and smarter outbreak response. The Thai Department of Diseases Control (DDC), the Department of Medical Sciences (DMSc), Ministry of Public Health have collaboratively worked with Chulalongkorn University (CU) and the Thai Red Cross Society (TRC) on HIV research and other emerging endemic infectious disease surveillance, prevention, and control. This proposal will launch the “Integrated Public Health and Academic Collaboration for Infectious Diseases Control (iPHAC- IDC): Implementation of One Health approaches to pandemic preparedness and adolescent HIV prevention”, a collaborative nested network among infectious disease control researchers from DDC, DMSc, CU and TRC, as well as EID experts in the USA and France. The iPHAC-IDC will establish an integrated and sustainable network to prepare for future disease outbreaks in Thailand. We will conduct research to 1) Develop and implement the NextGen Public Health Surveillance Approaches by using the PCR, next-generation sequencing, and multiplex serology assays to identify novel viruses, characterize the genomes of new-rare viral strains of endemic diseases, EIDs, and AMR. These genomic data will be integrated with clinical and epidemiologic data to create a pathogen genomic surveillance platform. In addition, genomic-mathematic models will be developed and embedded in the platform for real-time analysis. One Health surveillance approaches in the environment, including wastewater and air, and SARS-CoV-2 reverse zoonoses in wildlife will be pursued. 2) Develop and implement the GLLP curriculum at the School of Global Health by creating a GLLP curriculum at the Faculty of Medicine, Chulalongkorn University, in two pattern courses; A mandatory course in the One Health Branch of the Medical Sciences program and an elective course for other graduate students and a lifelong learning platform for all participants with an option to keep the credits for further claims after enrollment to CU. 3) Develop a youth-focused HIV prevention service model in the government hospital network by establishing youth-focused clinics that provide comprehensive HIV education and prevention with pre-exposure prophylaxis leveraging social network strategies, and improving gonorrhea antimicrobial genomics resistance surveillance. This research will advance our understanding of the risk of EIDs and endemic diseases and strengthen in- country public health research capacity and promote laboratory workforce development for pandemic preparedness and adolescent HIV prevention.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "12769", "attributes": { "award_id": "1I01BX004686-01A2", "title": "Calcium release-activated calcium (CRAC) channels in experimental traumatic brain injury", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2023-10-01", "end_date": "2027-09-30", "award_amount": null, "principal_investigator": { "id": 28673, "first_name": "Midori A", "last_name": "Yenari", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1522, "ror": "", "name": "VETERANS AFFAIRS MED CTR SAN FRANCISCO", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "This project will explore calcium-release-activated calcium channels (CRAC) as a potential therapeutic target in a laboratory model of traumatic brain injury (TBI). TBI is a common problem in the Veteran and civilian populations but definitive treatments are few. Microglia are the brain’s resident immune cell, and many studies have now shown that when activated, they contribute negatively to neurological outcome. Thus, strategies to inhibit microglial functions could prove therapeutic. Recent work has focused on the role of CRAC channels in inflammatory cells such as T cells, mast cells and neutrophils, and other inflammatory conditions such as autoimmune disease and acute pancreatitis; however, very little work has been published on CRAC channels as they pertain to microglia or inflammation in the brain. Past work has focused on calcineurin inhibitors such as cyclosporine A and FK 506 which act downstream of the CRAC channel, but have many off target effects and clinical toxicities which limit their use. These CRAC channel inhibitors are already being studied at the clinical level for other indications, and do not appear to have the same toxicities as the CNIs. In fact, a similar inhibitor produced by the same company was recently shown to improve outcome from severe COVID-19 pneumonia following infection with the SARS-CoV-2 virus, and was well tolerated in this patient population. Prior work in our lab showed that these specific CRAC channel inhibitors block microglial activation and that at least one of these inhibitors protects the brain from experimental TBI. This project will study CRAC channel inhibitors in a model of TBI to further define the conditions where neuroprotection may be observed. The first Aim will determine the more protective of two such novel CRAC channel inhibitors, and determine the optimal dosing required for maximum neurological benefit. This aim will also validate the specificity of the inhibitors and the expected mechanism of action of downstream calcium and inflammatory signaling. The second aim will then determine whether treatment can be delayed by hours and still show improvement in neurological outcomes. The third aim will then use the optimal dose and dosing regimen determined from the first two aims to see if any benefit is long lasting. In vivo experiments will include studies in female animals as well as comparing these novel, specific inhibitors to currently available, but less specific inhibitors.", "keywords": [ "2019-nCoV", "Acute", "Acute Brain Injuries", "Affect", "Animals", "Area", "Autoimmune Diseases", "Binding", "Biological Assay", "Biotechnology", "Brain", "Brain Injuries", "COVID-19", "COVID-19 pneumonia", "Calcineurin", "Calcineurin Pathway", "Calcineurin inhibitor", "Calcium", "Calcium Channel", "Cells", "Clinical", "Collaborations", "Cyclosporine", "Cytoprotection", "Dose", "Experimental Models", "FK506", "Female", "Hour", "Human", "Immune", "Immune response", "Immune signaling", "Immunosuppression", "In Vitro", "Infection", "Inflammation", "Inflammatory", "Inflammatory Response", "Injury", "Laboratories", "Length", "Mediating", "Microglia", "Modeling", "Mus", "Nervous System Trauma", "Neurologic", "Neurological outcome", "Outcome", "Pathway interactions", "Plasma", "Population", "Publishing", "Pulmonary Inflammation", "Regimen", "Regulation", "Role", "Signal Transduction", "Site", "Source", "Specificity", "Stroke", "T-Lymphocyte", "Tacrolimus", "Testing", "Therapeutic", "Toxic effect", "Translations", "Traumatic Brain Injury", "Up-Regulation", "Veterans", "Virus", "Woman", "Work", "acute pancreatitis", "brain tissue", "cohort", "effective therapy", "experimental study", "glial activation", "immunoreaction", "improved", "improved outcome", "in vivo", "inhibitor", "knock-down", "male", "mast cell", "men", "neuroprotection", "neutrophil", "novel", "patient population", "prevent", "response", "severe COVID-19", "side effect", "small molecule inhibitor", "stroke model", "therapeutic target" ], "approved": true } }, { "type": "Grant", "id": "12777", "attributes": { "award_id": "1I01CX002502-01A2", "title": "Long-Term Effects of COVID-19 on Cognitive Function and Mental Health", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2023-07-01", "end_date": "2026-06-30", "award_amount": null, "principal_investigator": { "id": 28679, "first_name": "DIANE", "last_name": "SWICK", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2157, "ror": "", "name": "VA NORTHERN CALIFORNIA HEALTH CARE SYS", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "The ongoing pandemic of COVID-19 continues to have a detrimental impact on society, even after the rapid development of safe and effective vaccines. The worst phases of the pandemic caused systemic and cultural shifts in education, work, commerce, social ties, and even the process of grieving. The SARS-CoV-2 virus has taken 6.5 million lives worldwide, over 1 million lives in the US, and nearly 23,000 Veterans receiving care in the VA system. The highly infectious Omicron variant has caused the largest surge of cases yet, with a peak in mid-January 2022. This variant causes milder symptoms but is more resistant to current vaccines. While the most severely affected COVID patients are rightfully the focus of many investigations, patients with milder disease may show lasting changes as well. An important study by Al-Aly, Xie, and Bowe (2021) identified all non-hospitalized Veterans who had at least one SARS-CoV-2 positive test and who survived 30 days after diagnosis. Six months later, those who had COVID had an excess burden of respiratory conditions, metabolic disorders, cardiovascular conditions, insomnia, fatigue, anxiety disorders, trauma-related disorders, and neurocognitive disorders. Follow-up studies found that many of these conditions can persist for at least one year (Xie et al., 2022a,b). In addition, the risk of adverse health outcomes increases in Veterans with multiple infections (Al-Aly et al., preprint). Although epidemiological studies have been helpful in identifying population-level trends, a key missing perspective can be provided by Veterans’ ratings of their own mental and physical symptoms. This is critical because future interventions require a deeper understanding of the challenges faced by Veterans with post-COVID conditions. The unique needs of Veterans include higher rates of the comorbidities commonly associated with a greater risk of negative COVID outcomes (diabetes, hypertension, and cardiovascular conditions). Ongoing cognitive issues after a COVID infection can also have a negative impact on employment and daily functioning. Cognitive dysfunction was the third most commonly reported symptom in a survey of the Long Covid community (Davis et al., 2021), yet \"brain fog\" remains scantly investigated, especially in Veterans. The proposed observational study will have a two group, prospective, repeated measure (3 time points) design with a study group and a closely matched healthy comparator group. The study group will be Veterans (n=300) who had a positive test for SARS-CoV-2 within the last 3-24 months but were not hospitalized. This population comprises the majority of VA patients with positive tests for SARS-CoV-2 (approximately 85-90%). Their results will be compared to healthy Veteran controls matched on demographic variables, pre-existing psychiatric conditions, and major comorbidities (n=300). Follow-up tests will be conducted six months and 12 months later. The project will obtain objective measures of cognitive performance over time and explore their relationship to mental health (anxiety, depression, PTSD) and other persistent post-acute sequelae of SARS-CoV-2 (PASC) symptoms (insomnia, fatigue) in COVID-19 survivors. Covariates will adjust for baseline scores, number of vaccines, and time since diagnosis. We will also examine the impact of multiple infections on mental health and cognitive outcomes. A validated web-based testing platform will obtain objective and reliable measures of sustained attention, executive function, episodic memory, and working memory. A better understanding of specific weaknesses in cognitive function over time is necessary to identify future intervention targets in the Veteran population with persistent post- COVID conditions. Our study will also establish the importance of monitoring the mental health of Veterans who have recovered from COVID-19. Those with persistent symptoms can be referred to appropriate services to improve their quality of life.", "keywords": [ "2019-nCoV", "Address", "Affect", "Anxiety", "Anxiety Disorders", "COVID diagnosis", "COVID-19", "COVID-19 diagnosis", "COVID-19 impact", "COVID-19 pandemic", "COVID-19 patient", "COVID-19 survivors", "COVID-19 test", "Cardiovascular system", "Caring", "Cognitive", "Commerce", "Communities", "Development", "Diabetes Mellitus", "Diagnosis", "Disease", "Education", "Employment", "Episodic memory", "Fatigue", "Follow-Up Studies", "Future", "Health", "Healthcare Systems", "Heart Diseases", "Hypertension", "Impaired cognition", "Impairment", "Individual", "Infection", "Intervention", "Investigation", "Literature", "Long COVID", "Measures", "Mental Depression", "Mental Health", "Metabolic Diseases", "Minority", "Modeling", "Monitor", "Observational Study", "Occupational", "Online Systems", "Outcome", "Outcome Measure", "Participant", "Patient Self-Report", "Patients", "Performance", "Persons", "Phase", "Population", "Post-Acute Sequelae of SARS-CoV-2 Infection", "Post-Traumatic Stress Disorders", "Printing", "Process", "Psyche structure", "Quality of life", "Recording of previous events", "Reporting", "Resistance", "Risk", "SARS-CoV-2 B.1.1.529", "SARS-CoV-2 positive", "Services", "Short-Term Memory", "Sleep", "Sleeplessness", "Societies", "Surveys", "Survivors", "Symptoms", "System", "Testing", "Time", "Trauma", "Vaccines", "Variant", "Veterans", "Virus", "Work", "associated symptom", "brain fog", "breakthrough infection", "cognitive function", "cognitive performance", "cognitive testing", "comorbidity", "comparison control", "comparison group", "coronavirus disease", "daily functioning", "design", "epidemiology study", "executive function", "follow-up", "improved", "long term consequences of COVID-19", "military veteran", "neurocognitive disorder", "pandemic disease", "persistent symptom", "physical symptom", "post-COVID conditions", "post-COVID-19", "prospective", "respiratory", "selective attention", "social", "social relationships", "sustained attention", "trend", "unvaccinated", "web platform" ], "approved": true } }, { "type": "Grant", "id": "13974", "attributes": { "award_id": "1IS1BX006324-01", "title": "ShEEP Request for MERSCOPE Instrument", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2023-03-01", "end_date": "2023-09-30", "award_amount": null, "principal_investigator": { "id": 30421, "first_name": "Franklin W", "last_name": "Huang", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1522, "ror": "", "name": "VETERANS AFFAIRS MED CTR SAN FRANCISCO", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Technological advances have now greatly expanded the frontier of single cell transcriptomics. We can now measure individual cells within their spatial context and directly observe cell-cell interactions. A leading technology in this area, named MERFISH, uses digital barcoding of mRNAs in the cell to measure gene expression at sub-cellular resolution. We propose to request the MERSCOPE instrument, which allows for MERFISH processing of hundreds of genes on tumor and tissue sections to advance our studies of cancer and other diseases that affect Veterans’ health. In situ hybridization (ISH)-based methods entail a process whereby a target sequence is detected by hybridization of a complementary fluorescent probe. The addition of sequential rounds of hybridization and imaging combined with barcoding have enabled substantial multiplexing. In multiplexed error-robust fluorescence ISH (MERFISH), successive rounds of hybridizations are imaged to detect the presence or absence of fluorescently labelled probes. The serial images are then decoded, using the error-robust barcode associated with each transcript identity. MERFISH has been used over a wide range of scales, from transcript location within individual cells to tissue-level spatial transcriptomics. Research projects advancing studies of diseases highly relevant to the Veterans’ community that will be supported by this instrument include studies focusing on cancers such as prostate and lung cancer, brain diseases, such as traumatic brain injury (TBI), frontotemporal dementia (FTD), and lung diseases. Spatial transcriptomics is required to simultaneously image multiple cells in affected tissues to determine cellular localization and gene expression. Lung transplant and pulmonary fibrosis studies will be served by this equipment to image specific cell types in lung transplant and fibrotic tissues. Infectious disease research projects related to HIV and SARS-CoV-2 will be able to utilize this instrument to better understand the pathogenic mechanisms of infection and persistence in tissues. Studies of prostate, hepatocellular, and lung cancer will also utilize this equipment to characterize prognostic biomarkers and understand the tumor microenvironment. We are excited to request the MERSCOPE, a state-of-the-art spatial transcriptomics instrument that will provide innovative and outstanding images for research studies to advance Veterans’ health. We anticipate the MERSCOPE to provide services essential towards accomplishing VA’s research goals to understand and treat diseases of high importance to the Veteran population.", "keywords": [ "2019-nCoV", "Address", "Affect", "Area", "Bar Codes", "Biological", "Brain Diseases", "COVID-19", "Cell Communication", "Cells", "Communicable Diseases", "Communities", "Community Services", "Computer software", "Custom", "Data", "Data Set", "Dedications", "Dementia", "Diagnosis", "Dimensions", "Disease", "Equipment", "Fluorescent Probes", "Fluorescent in Situ Hybridization", "Frontotemporal Dementia", "Funding", "Future", "Gene Expression", "Gene Expression Profiling", "Genes", "Goals", "HIV", "Health", "Health Services Research", "Image", "In Situ", "In Situ Hybridization", "Individual", "Infection", "Infectious Diseases Research", "Label", "Laboratory Research", "Location", "Lung Transplantation", "Lung diseases", "Malignant Neoplasms", "Malignant neoplasm of lung", "Malignant neoplasm of prostate", "Maps", "Measures", "Messenger RNA", "Methods", "Names", "Oligonucleotides", "Pathogenicity", "Primary carcinoma of the liver cells", "Process", "Prognostic Marker", "Pulmonary Fibrosis", "RNA", "Research", "Research Personnel", "Research Project Grants", "Resolution", "Resources", "San Francisco", "Services", "Sheep", "System", "Techniques", "Technology", "Tissues", "Transcript", "Traumatic Brain Injury", "United States Department of Veterans Affairs", "Urology", "Veterans", "Visualization", "cell type", "cellular imaging", "combinatorial", "complex data", "cost effective", "design", "digital", "experimental study", "frontier", "gene panel", "high resolution imaging", "innovation", "insight", "instrument", "interest", "laboratory facility", "lung injury", "military veteran", "research study", "serial imaging", "single molecule", "tool", "transcriptomics", "tumor", "tumor microenvironment" ], "approved": true } }, { "type": "Grant", "id": "13166", "attributes": { "award_id": "1I01RX004572-01A1", "title": "Modifying Adiposity Through Behavioral Strategies to Improve COVID-19 Rehabilitation", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2023-11-01", "end_date": "2028-10-31", "award_amount": null, "principal_investigator": { "id": 26754, "first_name": "ALICE S.", "last_name": "RYAN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 29208, "first_name": "Monica C", "last_name": "Serra", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1681, "ror": "https://ror.org/03n2ay196", "name": "South Texas Veterans Health Care System", "address": "", "city": "", "state": "TX", "zip": "", "country": "United States", "approved": true }, "abstract": "Findings of post-acute sequelae of Post-COVID Conditions (PCC) manifestations of fatigue, pain, dyspnea, and muscle weakness, provide a strong rationale for rehabilitation; yet few formal studies exist and the effects of severe acute respiratory syndrome coronavirus-2 infection on function are not well described. Notably, two- thirds of Veterans are overweight and obese, rendering excess adiposity a significant risk factor and a high- priority area related to PCC prevention and care. Obesity increases the risk of severe illness in Veterans recovering from PCC, but how it does so is not fully understood. Recent research suggests that excess adipose tissue is associated with adverse changes in adipose cellular function, and that these variations may be involved in the biology of aging and the etiology of aging- related diseases. Adipose tissue contains cells that have undergone cellular senescence, which induces inflammation, cytotoxicity, and metabolic dysfunction in other cells and tissues. However, the precise role of adipose tissue cellular composition on PCC recovery is limited. Thus, we propose to evaluate the role of obesity and PCC on physical functioning, health-related quality of life (HRQOL), and systemic and adipose tissue inflammatory and cellular senescence profiles in ethnically diverse older Veterans from the Audie Murphy (San Antonio) and Baltimore VA Medical Centers. Further, we propose a randomized controlled trial to determine whether a reduction in body weight and increased physical function by a weight loss intervention (WL), including dietary modification and exercise, in obese Veterans with PCC will reduce systemic and adipose tissue inflammation and senescence, which will have important implications for PCC recovery. We will pursue the following aims: Aim 1: To compare physical function, body composition, HRQOL, PCC symptoms, and adipose tissue molecular profiling in four cohorts of Veterans at baseline: lean PCC naïve, lean with PCC, obese PCC naïve, and obese with PCC (N=150). Aim 2: To compare in Veterans with obesity: a) a 12-week randomized WL vs. weight stability (WS) intervention (30/group) on physical function, body composition, HRQOL, and PCC symptoms together with changes in the global molecular profile in adipose tissue in Veterans with PCC and b) the WL intervention in PCC naïve vs. with PCC (N=30/group) on these outcomes. Older (55-80 years) men and women Veterans will be recruited. We will perform a standard functional battery (maximal aerobic capacity [VO2max; primary outcome], usual gait speed, six min walk distance, timed up and go, and handgrip strength), body composition (dual energy x-ray absorptiometry and computed tomography scans), HRQOL (NIH PROMIS-57), and PCC symptoms (COVID-19 Yorkshire Rehabilitation Scale [C19-YRS]) and adipose tissue will be collected. Further, we will test, in a randomized controlled trial, the hypothesis that a WL intervention, compared to weight stability (WS), improves physical function, body composition, and HRQOL and reduces inflammation and senescent cell burden and to a similar extent as the PCC naïve group with obesity. A deeper understanding of the relationship between adipose tissue and PCC will likely reveal factors that predispose to or protect against aging-related functional declines. Moreover, a better understanding of the effects of a lifestyle intervention on the molecular profile of adipose tissue will help to determine how changes in adipose tissue contribute to PCC and PCC recovery. Lastly, this research will provide important mechanistic insights into how cellular senescence influences the pathophysiology of physical, mental, and social dysfunction in older Veterans. Our findings could provide evidence-based recommendations to promote this type of intervention in Veterans recovering from PCC.", "keywords": [ "2019-nCoV", "Acute", "Adipose tissue", "Aerobic", "Aging", "Area", "Baltimore", "Behavioral", "Biological Assay", "Biology of Aging", "Body Composition", "Body Weight", "COVID-19", "COVID-19 impact", "COVID-19 prevention", "Caring", "Cell Aging", "Cell Cycle Arrest", "Cell physiology", "Cells", "Chronic", "Diet Modification", "Disease", "Dual-Energy X-Ray Absorptiometry", "Dyspnea", "Etiology", "Exercise", "Fatigue", "Fatty acid glycerol esters", "Functional disorder", "Gait speed", "Health", "Individual", "Inflammation", "Inflammatory", "Intervention", "Intramuscular", "Laboratories", "Life Style", "Long COVID", "Medical center", "Metabolic dysfunction", "Molecular Profiling", "Muscle Weakness", "Obesity", "Outcome", "Overweight", "Oxidative Stress", "Pain", "Participant", "Patient Self-Report", "Phenotype", "Physical Function", "Post-Acute Sequelae of SARS-CoV-2 Infection", "Predisposing Factor", "Prevention", "Psyche structure", "Randomized", "Randomized Controlled Trials", "Recovery", "Rehabilitation therapy", "Reporting", "Research", "Risk", "Risk Factors", "Role", "SARS-CoV-2 infection", "Sampling", "Scanning", "Symptoms", "Testing", "Thinness", "Tissue Banks", "Tissues", "United States National Institutes of Health", "VO2max", "Variant", "Veterans", "Visceral fat", "Walking", "Weight", "Woman", "X-Ray Computed Tomography", "clinical implementation", "cohort", "cytotoxicity", "disability", "ethnic diversity", "evidence based guidelines", "functional decline", "health related quality of life", "improved", "innovation", "insight", "lifestyle intervention", "men", "novel", "persistent symptom", "pharmacologic", "physical conditioning", "post-COVID conditions", "post-COVID-19", "primary outcome", "recruit", "response", "senescence", "social deficits", "weight loss intervention" ], "approved": true } }, { "type": "Grant", "id": "13171", "attributes": { "award_id": "1I01CX002616-01", "title": "Genetic predictors, pathophysiological mechanisms, and functional consequences of post-acute sequelae of SARS-CoV-2: Exercise challenge of gut microbiome and neuroinflammation in PASC", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2023-10-01", "end_date": "2027-09-30", "award_amount": null, "principal_investigator": { "id": 29215, "first_name": "DANE B.", "last_name": "COOK", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2247, "ror": "", "name": "WM S. MIDDLETON MEMORIAL VETERANS HOSP", "address": "", "city": "", "state": "WI", "zip": "", "country": "United States", "approved": true }, "abstract": "The long-term goals of this research are to determine the mechanisms that underlie Post-Acute Sequelae of SARSCoV-2 (PASC)-related symptoms in Veterans and to develop targeted and personalized treatments. PASC is a condition of long-term symptom burden following coronavirus disease 2019 (COVID-19) that is having serious adverse effects among Veteran populations. Known colloquially as Long-COVID, symptoms of pain, fatigue, irritable bowel, and cognitive impairment overlap considerably with chronic multisymptom illnesses (CMIs) such as myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and Gulf War illness (GWI). Critically, all three conditions report that physical activity worsens their illness, a characteristic of CMIs known as post-exertional malaise (PEM). As with CMIs, PEM is a promising model for studying Long-COVID in Veterans because, as we have shown in ME/CFS and GWI, PEM reveals pathophysiology not apparent at rest by challenging multiple physiological systems. The causes of PEM/CMIs are currently unknown, but converging evidence suggests that gut-microbiome perturbations and neuroinflammation act to sustain/worsen symptoms. Our central hypothesis is that neuroinflammation and gut-microbiome perturbations act to produce and maintain symptoms, and that dysfunction among these systems is best studied using an exercise challenge model. Our pilot data indicate that those with CMI: 1) report moderate-to-large symptom changes and worsened cognitive performance following a standardized exercise challenge; 2) show disturbed gut microbiome at rest and differential responses to exercise compared to controls, and 3) that peripheral inflammation (interleukin-6) is associated with augmented brain activity during fatiguing cognition in ME/CFS compared to controls. We intend to extend our exercise challenge research in CMI to PASC with the following specific aims: Aim 1: To determine the effects of a standardized exercise challenge on PEM (symptoms and cognition). Aim 2: To determine the effects of a standardized exercise challenge on gut microbiome structure and function. Aim 3: To determine the effects of a standardized exercise challenge on neuroinflammation. This study will significantly enhance our understanding of PASC and will begin to determine the pathophysiological mechanisms that underlie symptoms at rest and symptom worsening with physical effort. The COVID-19 pandemic offers a unique window of opportunity to evaluate pathophysiology early in disease development and with known proximity to the initiating event – i.e., COVID-19 infection. This is a rare occurrence in CMI research, and one that can provide critical mechanistic insight to aid in the development of targeted and personalized therapies.", "keywords": [ "2019-nCoV", "Acute", "Address", "Adverse effects", "Affect", "American", "Area", "Back", "Biological Markers", "Boston", "Brain", "COVID-19", "COVID-19 pandemic", "COVID-19 survivors", "Caring", "Characteristics", "Chicago", "Chronic", "Chronic Fatigue Syndrome", "Clinical", "Cognition", "Country", "Data", "Data Set", "Databases", "Development", "Disease", "Equilibrium", "Event", "Exercise", "Exertion", "Exhibits", "Fatigue", "Foundations", "Frequencies", "Functional disorder", "Gait", "Genetic", "Goals", "Health", "Impaired cognition", "Impairment", "Incidence", "Individual", "Inflammation", "Inflammatory", "Interleukin-6", "Intervention", "Intestines", "Investigation", "Life", "Long COVID", "Malaise", "Medical center", "Metagenomics", "Mission", "Modeling", "Neurologic", "Outcome", "Pain", "Participant", "Patient-Focused Outcomes", "Patients", "Peripheral", "Persian Gulf Syndrome", "Phenotype", "Physical Efforts", "Physical activity", "Physiological", "Population", "Positioning Attribute", "Positron-Emission Tomography", "Post-Acute Sequelae of SARS-CoV-2 Infection", "Proteins", "Recording of previous events", "Recovery", "Registries", "Reporting", "Research", "Research Infrastructure", "Research Personnel", "Research Priority", "Resources", "Rest", "Risk", "Risk Factors", "SARS-CoV-2 infection", "Science", "Services", "Severities", "Standardization", "Structure", "Study models", "Symptoms", "System", "Testing", "United States Department of Veterans Affairs", "Veterans", "Veterans Health Administration", "Work", "brain fog", "cognitive performance", "combat", "comparison control", "data management", "data warehouse", "effective intervention", "empowerment", "experience", "functional disability", "functional independence", "genetic predictors", "gut microbiome", "improved", "individualized medicine", "insight", "microbiome alteration", "military veteran", "negative affect", "neuroinflammation", "pain symptom", "patient population", "persistent symptom", "personalized medicine", "post-COVID conditions", "precision medicine", "predictive modeling", "programs", "receptor", "response", "systemic inflammatory response", "targeted treatment" ], "approved": true } } ], "meta": { "pagination": { "page": 1405, "pages": 1405, "count": 14046 } } }